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ATP6AP1 deﬁciency causes an immunodeﬁciency
with hepatopathy, cognitive impairment and
abnormal protein glycosylation
Eric J.R. Jansen1,*, Sharita Timal2,3,*, Margret Ryan4,*, Angel Ashikov2,3, Monique van Scherpenzeel2,3,
Laurie A. Graham4, Hanna Mandel5, Alexander Hoischen6, Theodore C. Iancu7, Kimiyo Raymond8,
Gerry Steenbergen3, Christian Gilissen6, Karin Huijben3, Nick H.M. van Bakel1, Yusuke Maeda9,
Richard J. Rodenburg3,10, Maciej Adamowicz11, Ellen Crushell12, Hans Koenen13, Darius Adams14,
Julia Vodopiutz15, Susanne Greber-Platzer15, Thomas Mu¨ller16, Gregor Dueckers17, Eva Morava18,19,20,
Jolanta Sykut-Cegielska21, Gerard J.M. Martens1, Ron A. Wevers3, Tim Niehues17, Martijn A. Huynen22,
Joris A. Veltman6,23, Tom H. Stevens4 & Dirk J. Lefeber2,3
The V-ATPase is the main regulator of intra-organellar acidiﬁcation. Assembly of this complex
has extensively been studied in yeast, while limited knowledge exists for man. We identiﬁed
11 male patients with hemizygous missense mutations in ATP6AP1, encoding accessory
protein Ac45 of the V-ATPase. Homology detection at the level of sequence proﬁles indicated
Ac45 as the long-sought human homologue of yeast V-ATPase assembly factor Voa1.
Processed wild-type Ac45, but not its disease mutants, restored V-ATPase-dependent growth
in Voa1 mutant yeast. Patients display an immunodeﬁciency phenotype associated with
hypogammaglobulinemia, hepatopathy and a spectrum of neurocognitive abnormalities.
Ac45 in human brain is present as the common, processedB40-kDa form, while liver shows
a 62-kDa intact protein, and B-cells a 50-kDa isoform. Our work unmasks Ac45 as
the functional ortholog of yeast V-ATPase assembly factor Voa1 and reveals a novel link of
tissue-speciﬁc V-ATPase assembly with immunoglobulin production and cognitive function.
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T
he vacuolar Hþ -ATPase (V-ATPase) is a ubiquitously
expressed protein complex, required for luminal
acidiﬁcation of secretory vesicles to acidify the extracellular
milieu, compartments of the endocytic pathway including
lysosomes, and of the Golgi apparatus1,2. The V-ATPase
consists of two multi-protein domains, V1 and V0. The
peripheral V1 domain comprises eight subunits (A–H), is
localized in the cytoplasm and hydrolyses ATP. The V0 domain
is embedded in the organelle membrane, consists of ﬁve subunits
(a, d, e, c and c00) and harbours the rotary mechanism for proton
translocation2. Human disease mutations in V-ATPase core
subunits result in distinct clinical syndromes. In 1999, renal
tubular acidosis with deafness was the ﬁrst phenotype linked to
the V-ATPase with mutations in the kidney-speciﬁc isoforms
ATP6V1B1 (MIM 267300) or ATP6V0A4 (MIM 602722)
(refs 3–5). In 2000, osteopetrosis (MIM 259700) was linked to
the V-ATPase by identiﬁcation of mutations in TCIRG1,
encoding the osteoclast-speciﬁc a3 subunit6,7. In 2008,
mutations were found in ATP6V0A2 in a subgroup of cutis laxa
syndromes with abnormal protein glycosylation, autosomal
recessive cutis laxa type II (MIM 219200&278250). ATP6V0A2
encodes the a2 subunit, which localizes the V-ATPase complex to
the Golgi apparatus8.
In addition to the core V-ATPase subunits, two accessory
proteins are known in vertebrates, that is, ATP6AP1 (also known
as Ac45) and ATP6AP2 (also known as (Pro-) renin receptor)9.
In vertebrates, Ac45 is ubiquitously expressed with the
highest levels in neuronal and (neuro-) endocrine cells and
osteoclasts10–13. This accessory subunit of the proton pump
guides the V-ATPase into specialized subcellular compartments
such as neuroendocrine regulated secretory vesicles14,15 or the
rufﬂed border of the osteoclast10,16,17 thereby regulating its
activity. Moreover, the Ac45 protein is involved in membrane
trafﬁcking and Ca2þ -dependent membrane fusion18. V-ATPase
assembly has been extensively studied in yeast, where Vma21,
Vma12 and Vma22 cooperate in the assembly of the V0 domain
in the endoplasmic reticulum (ER) membrane19–23. Additionally,
yeast Voa1 has been established as an ER-localized V0-assembly
factor in 2008. However, no human orthologue has been
identiﬁed so far24. In human, V-ATPase assembly is hardly
studied, and no yeast orthologue of human Ac45 has thus
far been identiﬁed9,25–27.
In this study, we describe a novel ATP6AP1-linked immuno-
deﬁciency and identiﬁed disease mutations in ATP6AP1 in
11 male patients with abnormal protein glycosylation. Yeast
V-ATPase assembly factor Voa1 was predicted to be homologous
to Ac45, which was conﬁrmed by functional complementation of
Voa1 mutant yeast with the processed C-terminal domain of
Ac45. Identiﬁcation of different Ac45 protein isoforms in human
brain, liver and B cells indicated the presence of tissue-speciﬁc
regulation of organelle acidiﬁcation.
Results
Identiﬁcation of mutations in X-linked ATP6AP1. In our
cohort of unsolved patients with deﬁcient glycosylation of
proteins, we performed exome sequencing to identify the
causative gene defect. Exome sequencing of a male patient
(individual 1.1, Table 1) was performed as previously described28.
After ﬁltering out poor-quality variants as well as common and
synonymous variants (see Methods section), 131 rare missense
variants were selected. Based on a recessive inheritance model,
two candidate genes remained (Supplementary Table 1):
X-linked ATP6AP1 with hemizygous variant and KPRP on
Chr1 with compound heterozygous variants. Of these variants,
the c.1284G4A variant in ATP6AP1 on chrXq28 showed the
highest level of conservation (PhyloP 46-way, 5.1) and
was predicted to be pathogenic by Sift, Polyphen-2 and
MutationTaster. Moreover, no potentially pathogenic variants
were identiﬁed in KPRP in the WES data of patients 2.1 and 6.1.
ATP6AP1 encodes the accessory subunit Ac45 of the V-ATPase
complex13, the proton pump that has been linked with abnormal
glycan processing in the Golgi via mutations in its core subunit
ATP6V0A2 (ref. 8). Sanger sequencing conﬁrmed the hemizygous
missense mutation (c.1284G4A, p.M428I) in the patient as well
as in two affected male family members that became known
during the sequencing process (Fig. 1). All maternal alleles
showed heterozygosity and healthy males were hemizygous wild
type (Supplementary Fig. 1A), conﬁrming complete segregation
of the c.1284G4A mutation with disease in agreement with
X-linked inheritance. Exome and Sanger sequencing of ATP6AP1
in a cohort of unsolved male patients with abnormal protein
glycosylation revealed additional mutations in eight patients from
ﬁve families (Table 1, Supplementary Fig. 1B). Patient 2.1 showed
a c.431T4C (p.L144P) missense mutation, heterozygous in
the mother and absent from the father and a healthy sister.
An additional hemizygous missense mutation (c.1036G4A,
p.E346K) was identiﬁed by Sanger sequencing in three non-
related male sib pairs (families 3–5). Fathers carried wild-type
alleles and mothers were heterozygous for the c.1036G4A
variant, in agreement with X-linked inheritance. Exome
sequencing of patient 6.1 revealed a c. 938A4G (p.Y313C)
missense mutation.
All four missense mutations (L144P, Y313C, E346K and
M428I) affect amino acids that are highly conserved down to
fruitﬂy, tetraodon and frog (Supplementary Fig. 1C). Ac45
homologues in more distantly related species could not readily
be retrieved by use of standard BLAST searches. L144P is located
in the N-terminal domain, while Y313C, E346K and M428I are
located in the processed C-terminal domain of Ac45 (Fig. 1b).
Clinical phenotype of Ac45 deﬁciency. The dominating clinical
symptoms displayed by the present cohort of patients with
various ATP6AP1 mutations (Table 1) include hepatopathy
and immune abnormalities. Recurrent bacterial infections were
associated with hypogammaglobulinemia, ranging from plantar
abscesses and gastrointestinal infections in family 1 to multiple
episodes of childhood pneumonia and purulent otitis media in
families 2–6. Several patients were successfully treated with
intravenous immunoglobulins. Of note, some of the patients
responded very poorly to childhood vaccinations. Hepatopathy
ranged from mild hypertransaminasemia to cirrhosis and
end-stage liver failure. In addition, gastric problems were noted in
the majority of patients and laboratory abnormalities included
leukopenia, slightly elevated serum transaminases, low serum
copper and ceruloplasmin, and high alkaline phosphatase. The
two brothers from family 4 displayed high-normal levels of
IgDþ /CD27 naı¨ve B cells and lowered levels of IgDþ /
CD27þ intermediate and switched memory B cells, suggesting a
problem in B-cell differentiation.
Patients with the p.E346K substitution (families 3–5) showed
in addition splenomegaly, abnormal hepatic histology and
neurological symptoms such as epilepsy, mild intellectual
disability and behaviour abnormalities. Muscle weakness with
mildly elevated serum creatine kinase (CK) was demonstrated in
a few patients, including patient 6.1. Of note, the presence of the
p.E346K mutation predicted a more severe phenotype within the
ATP6AP1 disease spectrum, which is in accordance with the early
death of two patients (3.2 and 5.1) due to liver failure. Patients
from families 1, 2 and 6 display a milder disease course and are
currently doing well without cognitive impairment.
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The index family (substitution p.M428I) presented with a
milder disease course (oldest patient 34 years of age). All three
patients in this kindred presented with sensorineural hearing loss
to various extents and hyperopia. The grandmother also
presented deafness at older age. The vision abnormality was
documented also in patients 3.1 and 4.1 (E346K substitution).
Female carriers did not show any obvious clinical symptoms.
In the total cohort of patients, only minor clinical symptoms
were observed that overlap with symptoms from known genetic
defects in the V-ATPase, including deafness (ATP6V1B1 and
ATP6V0A4) and muscle weakness, as reported for X-linked
Myopathy with Excessive Autophagy (XMEA, MIM 310440) due
to mutations in V-ATPase assembly factor VMA21 (ref. 29).
When performed, radiography showed no signs of osteopetrosis
as observed in ATP6V0A3 deﬁciency. There was no apparent
renal phenotype with no signs of metabolic acidosis.
Hypokalemia was reported for patients 3.1 and 5.1. In general,
no signs for renal tubulopathy as observed in ATP6V0A4
deﬁciency were seen.
Liver biopsy ﬁndings. Liver biopsy was performed in six patients
and was (near)-normal for patients 1.3 and 2 (with the sub-
stitutions p.M428I and p.L144P, respectively), but revealed
steatosis, ﬁbrosis and even micronodular cirrhosis in patients
with the p.E346K mutation (Table 1, Supplementary Fig. 2).
Electron microscopy was performed in a liver tissue specimen of
patient 3.1 (Fig. 2). Hepatocytes showed variable translucency due
to the presence of noticeable proliferating smooth endoplasmic
reticulum, and of numerous alpha-glycogen monoparticles,
accumulated within the cell centre. At the periphery,
mitochondria were disposed along the plasma membrane (in a
mode similar to that observed in glycogen storage diseases).
Mitochondria were of usual size but frequently showed cristolysis
and occasional absence of cristae. The dense-matrical bodies were
preserved. No intra-mitochondrial crystals were noticed. Within
hepatocytes, fat globules with the typical shape and size of
triglycerides were seen, in variable amounts (Fig. 2a,
Supplementary Fig. 2). Their sizes varied from small (1.5–6.0 nm)
to medium (8.0–20 nm) and rarely large (21–40 nm). Lysosomes
(single limit membrane) were identiﬁed as typical (Fig. 2b,
arrows) and atypical lipofuscin bodies. The latter showed a
central electron-lucent accumulation with a reticular network
(Fig. 2c, arrows). Mitochondria were seen occasionally within
phagosomes (autophagocytosis, Fig. 2d, arrow). No dilated or
enlarged Golgi apparatus was detected in hepatocytes.
Ac45 deﬁciency alters Golgi processing of protein glycans.
Analysis of protein N-glycosylation in serum showed abnormal
proﬁles of transferrin in all studied patients (Fig. 3a,
Supplementary Table 3). In addition, mucin type O-glycosylation
of serum apolipoprotein CIII was abnormal in most patients,
showing decreased sialylation. This combination of abnormal
proﬁles is comparable with other defects of Golgi homoeostasis,
such as ATP6V0A2-CDG (ref. 8). In patients 3.2 and 5.1 normal
mucin type O-glycosylation was observed with even increased
sialylation in patient 5.1. This might complicate recognition of
Ac45-deﬁcient patients as a genetically determined glycosylation
disorder, since highly similar proﬁles are observed in patients
with non-speciﬁc liver disease. Considerable variation in
glycosylation abnormalities was observed in some of the
Table 1 | ATP6AP1-deﬁcient patients: genetic, clinical and laboratory data.
Family 1 Family 2 Family 3 Family 4 Family 5 Family 6
Individual 1.1 1.2 1.3 2 3.1 3.2 4.1 4.2 5.1 5.2 6
Sex Male Male Male Male Male Male Male Male Male Male Male
Current age 20 y 12 y 34 y 14 y 8 y Died at 4 y 23 y 18 y Died at 12 m 3 y 4 y
Consanguinity Yes Yes Yes None None None None None None None None
Ethnicity Caucasian Caucasian Druze Caucasian Tunesian Irish
Genetic and biochemical data
Mutation cDNA c.1284G4A c.431T4C c.1036G4A c.1036G4A c.1036G4A c.938A4G
Mutation protein p.Met428Ile (M428I) p.Leu144Pro
(L144P)
p.Glu346Lys (E346K) p.Glu346Lys (E346K) p.Glu346Lys (E346K) p.Tyr313Cys (Y313C)
Glycosylation
defect
NþO NþO NþBO NþO NþO N NþO NþO N NþO NþO
Clinical symptoms and signs
Onset of
symptoms
Neonatal jaundice ND Hospitalization
at 2 months due
to pneumonia
Recurrent
purulent otitis
since 7
months
Liver failure
following bloody
diarrhoea at 8
months
Jaundice and
hepatosplenomegaly at 1 month
Abdominal pain and hepatopathy at 1
month
Lymphadenopathy,
hepatomegaly,
abnormal liver
function tests
during respiratory
illness at 18 months
Liver
Hepatomegaly þ /    þ þ þ þ þ þ þ
Liver biopsy ND ND Normal Slight steatosis Fibrosis,
steatosis,
cirrhosis
Steatosis, cirrhosis, Micronodular
cirrhosis
Micronodular
cirrhosis
Fibrosis,
cirrhosis,
cholestasis, fat
liver 460%
ND Nodularity with
extensive bridging
ﬁbrosis, cirrhosis,
macrovesicular
steatosis
Neonatal
icterus
þ þ  þ   þ þ   
Splenomegaly     þ þ þ þ þ  
Infections þ þ þ þ þ þ þ þ þ þ þ
Neurologic
symptoms
 þ /   þ þ þ þ þ þ 
Laboratory abnormalities
Hypogammaglo-
bulinemia
þ þ þ þ þ þ þ þ þ þ þ (Low IgG)
IgG 8 y 620
(1,160–
1,860mg dl 1)
9 y 507 (853–
1,440mg dl 1)
30 y 1,020
(1,160–
1,860mg dl 1)
No data before
IVIG
3 y 521 (680–
1,560mg dl 1)
8 m 382 (680–
1,560mg dl 1)
1.6 y 155
(350–
1,180mg dl 1)
1 y 148 (350-
1.180mg dl 1)
8 m
o195mg dl 1
2 wks normal 4 y 352
(370–1,580mg dl 1)
IgG1: 177
(380–880mg dl 1)
IgM ND ND ND 13 y 24.4
(61–135mg dl 1)
3 y 64 (40–
280mg dl 1)
8 m 671 (680–
1,560mg dl 1)
1.6 y 67 (36–
104mg dl 1)
5.7 y o15
(40–
180mg dl 1)
1 y o15 (36–
104mg dl 1)
1.4 y 15 (40–
180mg dl 1)
7m 34.3 (30–
183mg dl 1)
2wks 7.4
(30–183mg dl 1
4 y Normal
IgA ND ND ND 13 y 9.6 (77–
260mg dl 1)
3 y 189 (70–
350mg dl 1)
8 m 285 (680–
1,560mg dl 1)
1.6 y 54 (36–
165mg dl 1)
1 y 38 (36–
165mg dl 1)
4m 14,3 (17–
96mg dl 1)
2wks o6,3 (17–
96mg dl 1)
4 y Normal
Leucopenia þ þ þ þ Only during
severe sepsis
 þ þ   
Increased
transaminases
þ / þ / þ / þ / þ / þ / þ þ þ þ þ
Low serum
copper
þ þ ND þ þ þ þ þ þ þ þ /
IVIG, intravenous immunoglobulin; ND, no data; m, months; wks, weeks; y, year; NþBO, borderline abnormal O-glycosylation.
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patients tested (3.1 and 3.2). Mass spectrometry of total serum
N-glycans revealed minor accumulations of truncated glycans
(Fig. 3b) and no overlapping glycan signature could be regarded
as speciﬁc for Ac45 deﬁciency. Mass spectrometric analysis of
isolated transferrin revealed a clear accumulation of similar types
of truncated glycans lacking galactose and sialic acid in all
patients (Fig. 3c, Supplementary Fig. 3).
Differential processing of Ac45 in liver, brain and B cells. We
studied ATP6AP1 expression in human fetal and adult tissues.
Both in fetal (data not shown) and adult tissues, the highest Ac45
mRNA expression was found in brain and the lowest expression
level in liver and duodenum (Supplementary Fig. 4). To study
Ac45 expression at the protein level, we performed western blot
analysis of mouse cortex, human brain and liver, and human B
cells using an Ac45 antibody directed to the C-terminal half of
mouse Ac45. Ac45 is synthesized as a 62-kDa precursor protein
(intact-Ac45) that in neuronal and neuroendocrine cells is sub-
sequently processed to its B40-kDa cleaved form (cleaved-Ac45
(refs 12,13,15,30), Fig. 4a). In mouse and human brain, most
Ac45 protein was present in its cleaved B40 kDa form, with
human Ac45 migrating slightly faster than its mouse counterpart
(Fig. 4b, lanes 1 and 3). Furthermore, and in-line with earlier
studies in Xenopus neuroendocrine cells31, these proteins were
N-glycosylated as shown by their sensitivity towards
endoglycosidase PNGaseF (Fig. 4b, lanes 2 and 4). These results
are in agreement with the slightly lower molecular mass of human
Ac45 as compared with mouse Ac45 and the presence of one
extra N-glycan on mouse Ac45. In addition, in human brain a
thus far unknown 50-kDa form was observed. In human and
mouse liver, considerable Ac45 protein expression was observed,
predominantly as the 62-kDa intact proteoform. Under the
conditions used, this band was insensitive to PNGaseF treatment
(Fig. 4b, lanes 5 and 6). Western blot analysis of primary B-cell
isolates as well as B-cell lines (data not shown) revealed Ac45
as an B50-kDa protein isoform (Fig. 4c). Analysis of Ac45
protein expression in patient liver biopsy material revealed a
strong reduction in the expression of the B62- and B40-kDa
Ac45 variants and an additional B50-kDa protein was observed
(Fig. 4d).
Subsequently, we performed newly synthesized protein label-
ling with 35S methionine in immortalized human hepatocytes
Family I
I:
II:
III:
•
P 1.1
c.1284G>A
•
•
P1.2
c.1284G>A
P1.3 
c.1284G>A
a
Chr X
c.1284G>A
ATP6AP1
gene
L1
44
P
E3
46
K
M
42
8I
Human 
Ac45
protein
b
c.431T>C c.1036G>A
TM
W425-L446
CS
R228-R231
SP
M1-A41
c.938A>G
Y3
13
C
p2
2.
33
p2
2.
31
p2
2.
2
p2
2.
12
p2
2.
11
p2
1.
3
p2
1.
1
p1
1.
4
p1
1.
3
p1
1.
23
p1
1.
22
p1
1.
21
p1
1.
1
q1
1.
1
q1
2
q1
3.
1
q2
1.
1
q2
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31
q2
1.
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q2
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1
q2
2.
3
q2
3
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4
q2
5
q2
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2
q2
6.
3
q2
7.
1
q2
7.
3
q2
8
Figure 1 | Overview of identiﬁed ATP6AP1 mutations. (a) Pedigree of index family 1. Black arrow (m) indicates the index patient P1.1 with the mutation
c.1284G4A (p.Met428Ile). (b) ATP6AP1 gene, located on chromosome Xq28, and its gene structure consisting of 10 exons. All mutations identiﬁed in the
six families are indicated in boxes. Domain structure of Ac45 as published on uniprot.org for human Ac45 (http://www.uniprot.org/uniprot/Q15904;
Entry version 146, 07 January 2015). CS, furin proteolytic cleavage site30; SP, signal peptide; TM, transmembrane region. Stars (%) indicate the location of
the mutations at the protein level. See also Supplementary Fig. 1.
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(IHH), after transfection with GFP (mock) and wild-type human
Ac45 complementary DNA. Immunoprecipitation with the Ac45
antibody revealed a dominant B62-kDa newly synthesized
endogenous as well as exogenous Ac45 form (Supplementary
Fig. 5A). Tunicamycin treatment of the IHH cells as well as
PNGaseF digestion after labelling and immunoprecipitation
revealed an B50-kDa Ac45 form, conﬁrming N-glycosylation
of the 62-kDa Ac45 isoform. In addition, EndoH sensitivity
indicates the presence of high mannose glycans (Fig. 4e).
Transfection of IHH cells with clinically relevant mutant
Ac45 constructs showed similar expression as wild type
(Supplementary Fig. 5B).
The subcellular localization of Ac45 in hepatocytes was studied
by immunostaining of IHH cells. Ac45 was found to be mainly
localized to the ER, and ER-to-Golgi Intermediate Compartment
(ERGIC), but not to the trans-Golgi network (TGN) or
components of the endosomal system (Fig. 4f, Supplementary
Fig. 6).
Human Ac45 is orthologous to yeast Voa1 and Big1. Orthologs
of Ac45 were readily identiﬁed by BLAST among the metazoa,
including nematodes like Caenorhabditis elegans, but not outside
of that taxon, leading to speculations about a role of Ac45 in
specialized and complex vacuolar systems in multicellular
organisms25. Nevertheless, the degree of sequence identity
between vertebrate and invertebrate members of the protein
family is relatively low, suggesting a high rate of sequence
evolution as an alternative explanation for the inability to detect
non-metazoan homologues. Using orthology prediction at the
level of sequence proﬁles32, we detected two S. cerevisiae Ac45
homologues: Voa1 and Big1. Voa1’s C-terminal transmembrane
helix is signiﬁcantly similar to the C terminus of Ac45
(E¼ 9.1e 5) (Fig. 5a), while the sequence similarity of Ac45 to
Big1 (E¼ 3.6e 10) is mainly restricted to the N-terminalB250
amino-acid residues of Ac45 and therewith coincides with the
part of Ac45 that is proteolytically cleaved by furin9,30. No
signiﬁcant sequence similarity could be detected in the dotted
lines, or for the comparison of the C-terminal helix of Big1 with
Ac45. Both proteins are located in the ER membrane, where Voa1
has been implicated in assembly of the V0 domain of the
V-ATPase24 while Big1 is essential for beta 1,6 glucan synthesis33.
Phylogenetic analysis shows that BIG1 and VOA1 appear the
result of a gene duplication in the Saccharomycotina phylum of
the Fungi (Supplementary Fig. 7B), indicating that both are
orthologous to Ac45. Interestingly, the evolutionarily conserved
residues between Voa1 and Ac45 are at a distance of 3–4 amino
acids from each other (Fig. 5a) and concentrate on one side of the
predicted transmembrane helix (Supplementary Fig. 7A),
potentially forming a conserved interaction interface. Using
iterative proﬁle-based homology searches34, we conﬁrmed the
homology between the Ac45 and Voa1, Big1, and also detected
homologues of Ac45 in major taxa of the eukaryotes, amoebozoa
(Dictyostelium discoideum), brown algae (Ectocarpus siliculosis)
and plants (Supplementary Fig. 7C). Ac45 orthologs in the
model species Arabidopsis thaliana (AT3G13410) and
Schizosacharomyces pombe (S. pombe) (SPCC306.06c) have, like
Ac45, Voa1 and Big1, been observed in the ER35,36, indicating
that the evolutionary origin of Ac45 lies at the root of the
eukaryotes.
Processed Ac45 functions in place of Voa1 in S. cerevisiae. In
yeast, Vma21 and Voa1 are assembly factors of the V-ATPase V0
domain in the ER membrane. Both are retained in the ER via a
C-terminal dilysine motif. When this motif is mutated to
diglutamine, the resulting Vma21QQ or Voa1QQ protein is
mislocalized to the vacuole with concomitant reduction in
V-ATPase assembly and activity. The effect on V-ATPase
assembly is cumulative, becoming most apparent when Voa1 is
absent (voa1::H) or Voa1QQ is expressed in vma21QQ cells24.
Yeast lacking functional V-ATPase have a characteristic
growth phenotype: they are unable to grow on medium buffered
to pH 7.5, or medium containing elevated levels of calcium, or a
combination of the two stressors24,37,38. Reduced V-ATPase
function can be detected by reduced growth under any of these
conditions. A growth assay on rich medium supplemented with
100mM CaCl2 was used to assess the ability of human Ac45 to
substitute for Voa1 (Fig. 5b,c). Full-length or processed Ac45
proteins with or without a dilysine motif (KKNN) appended to
the C terminus were expressed in a voa1::H vma21QQ strain.
Cells expressing full-length Ac45 grew poorly, comparable to cells
b
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dc
1 µm 
0.5 µm 0.5 µm
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a
Figure 2 | Ultrastructural studies of a liver biopsy of patient 3.1. (a) A hepatocyte is surrounded by fat globules of variable size having the typical aspect
of triglycerides, 4,000. (b) Hepatocyte showing relative translucency due to proliferated SER. Arrows point to lipofuscin bodies (lysosomes), 6,000.
(c) Higher magniﬁcation showing an atypical lipofuscin body with a central reticulate content (black arrow). White arrow: section through a Golgi
apparatus,  10,000. (d) A mitochondrion is engulfed in an autophagosome (arrow). BC, Bile canaliculus,  12,000.
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transformed with empty vector or cells expressing Voa1QQ.
Adding a dilysine motif to full-length Ac45 did not signiﬁcantly
improve growth. Conceivably, Ac45 function is dependent
on proper processing of the protein, which might not be
accomplished in yeast. Therefore, simulating a processed Ac45
protein12,14,15, the C-terminal half of Ac45 was expressed. This
processed Ac45 was able to function in place of Voa1, but only
when expressed with a dilysine motif (cleaved-Ac45-KKNN in
Fig. 5c). By complementation, cleaved-Ac45-KKNN function is
comparable to that of Voa1.
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Figure 3 | Glycosylation studies. (a) Routine screening for N-glycosylation by isofocusing of serum transferrin and for mucin type O-glycosylation by
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NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11600 ARTICLE
NATURE COMMUNICATIONS | 7:11600 | DOI: 10.1038/ncomms11600 |www.nature.com/naturecommunications 7
DAPI GFP Merge DIC
Voa1
Voa1QQ
Cleaved-Ac45-KKNN
Cleaved-Ac45
e
voa1::H vma21QQ
1 Voa1
2 Cleaved-Ac45-KKNN
3 Cleaved-Ac45-KKNN
Y313C
4 Cleaved-Ac45-KKNN
E346K
5 Cleaved-Ac45-KKNN
M428I
6 Empty plasmid
pH 5 60 mM CaCl2
pH 7.5
150
250
100
75
50
37
25
20
15
1 2 3 4 5 6
Ac45
Voa1
Vma21QQ
c
voa1::H vma21QQ
pH 5 100 mM CaCl2
Voa1
Voa1QQ
Cleaved-Ac45-KKNN
Intact-Ac45-KKNN
Intact-Ac45
Cleaved-Ac45
Empty plasmid
d
Voa1
Intact-
Ac45-KKNN
Cleaved-
Ac45-KKNN KKNN
M428E346Y313
251 470
KKNN
43 470
TM
TM
26 265
KKNN
HA or
HA-GFP
TMSP
SP
SP
b
a
E=3.8e –16 E=3.6e –10
E=4.3e –8 E=9.1e –5
E=0.1 E=2.9
CS
Big1 Big1
Voa1
Ac45SP TM
Ac45(420)
Voa1(217)
(450)
(247)
SFFSPGIWMGllTSLFMLFIFTYGLHMILSL
SIWTEGLLMCLIVSALLLFILIVALSWISNL
Figure 5 | Identiﬁcation of Voa1 as the yeast ortholog of human Ac45. (a) Overview of the regions of Ac45 that are homologous to the yeast proteins
Voa1 and Big1 and an alignment of Ac45’s and Voa1’s C-terminal transmembrane helices (in blue, based on TMHMM63) and their ﬂanking amino acids.
Ac45 and Voa1 are separated by a sequence logo representation of this region among all the homologs that could be detected using JACKHMMER64.
A pattern in which the level of sequence conservation in the transmembrane helix peaks every 3–4 amino acids is indicated with arrows. (b) Schematic of
Voa1 and Ac45 proteins expressed from centromere plasmids in voa1::H vma21QQ yeast24. Ac45 proteins are either full length (intact-Ac45) or processed
(cleaved-Ac45), with (shown) or without KKNN appended to the natural C terminus. Numbers indicate amino-acid residues. Residues mutated in Ac45 are
shown. (c) Cleaved-Ac45 can substitute for Voa1 when a C-terminal dilysine motif is present. The voa1::H vma21QQ strain was transformed with plasmids
coding for the indicated proteins (HA-tagged, diagrammed in (b)), Voa1QQ denotes Voa1 with K262Q and K263Q mutations. (d) The Y313C or E346K
mutation in cleaved-Ac45-KKNN reduces V-ATPase function while protein levels are unaffected. Serial dilution growth test of voa1::H vma21QQ yeast
expressing the indicated proteins tagged with HA. Restrictive growth is on rich medium adjusted to pH 7.5 and supplemented with 60mM CaCl2.
Membrane proteins prepared from the same cultures used in the growth test were analysed by western blot using anti-HA antibody to detect Voa1,
cleaved-Ac45-KKNN and its mutant forms (band locations marked on the right, molecular mass (kDa) is indicated on the left. (e) Voa1 and cleaved-Ac45
require a C-terminal dilysine motif for ER localization. Fluorescent microscopy of live yeast cells showing DAPI stained DNA, GFP, the merged image of
both, and cells viewed by differential interference contrast (DIC) to locate the vacuole as apparent indentation. The indicated proteins are N-terminally
tagged with HA-GFP and expressed in voa1::H vma21QQ yeast cells. Exposure times for GFP images of cleaved-Ac45 were 10 longer than for Voa1 or
Voa1QQ. Perinuclear GFP ﬂuorescence indicates ER localization. Mutated and non-mutated cleaved-Ac45-KKNN show the same localization. See also
Supplementary Fig. 7.
ARTICLE NATURE COMMUNICATIONS | DOI: 10.1038/ncomms11600
8 NATURE COMMUNICATIONS | 7:11600 | DOI: 10.1038/ncomms11600 |www.nature.com/naturecommunications
Growth assays were used next to measure the effect of three
pathogenic Ac45 substitutions, Y313C, E436K or M428I (Fig. 5d,
left panels). The mutations were introduced into cleaved-Ac45-
KKNN and expressed in voa1::H vma21QQ yeast. Growth was
tested on rich medium supplemented with 60mM CaCl2 and
buffered to pH 7.5. Cells expressing Y313C or E346K mutant
protein showed a growth defect, with the E346K mutant most
severely compromised, exhibiting reduced growth nearing that of
yeast having no Voa1. The effect of the M428I substitution was
less disruptive and appeared indistinguishable from non-mutated
Ac45. To ascertain that the growth defect observed for the Y313C
or E346K substitution was not the result of protein instability,
membrane proteins from the cells used in the growth assay
were examined by western blot (Fig. 5d, right panel). While Ac45
protein levels were lower than Voa1, levels for mutated
Ac45 proteins were unchanged compared with non-mutated
Ac45 protein. Therefore, reduced V-ATPase function observed
for the Y313C or E346K mutation cannot be ascribed to
decreased protein abundance.
Since both Voa1 and processed Ac45 require a dilysine motif
for function, it is expected that, like Voa1, processed Ac45-KKNN
is retained in the ER membrane, while absence of the motif would
result in mislocalization to the vacuole. This was tested using
GFP-tagged proteins (Fig. 5e, Supplementary Fig. 8). Though
GFP-tagging slightly reduced ﬁtness of processed Ac45-KKNN on
restrictive medium (data not shown), dilysine-dependent ER
localization was veriﬁed. Together with growth assay results, these
results indicate that the human and yeast proteins function about
equally well in V0 V-ATPase assembly in the ER.
Discussion
Much has been learned about V-ATPase function and assembly
by studies in yeast, however, studies in human have been very
limited. The clinical symptoms resulting from Ac45 deﬁciency,
mostly affecting the liver, immune system and brain, signiﬁcantly
differ from other known human genetic defects in various
V-ATPase subunits. Disease mutations in subunits of the V0
domain result in, respectively, renal tubular acidosis with deafness
(ATP6V0A4 (MIM 602722) (refs 3–5)), osteopetrosis (TCIRG1 or
ATP6V0A3 (MIM 259700) (refs 3,6,7)) and cutis laxa with
abnormal glycosylation (ATP6V0A2 (MIM 219200&278250)
(ref. 8)). One subunit of the V1 domain is linked to human
genetic disease (ATP6V1B1 (MIM 267300)) resulting in renal
tubular acidosis with deafness, while previously one of the
V-ATPase assembly factors, VMA21, has been linked to XMEA
(X-linked myopathy with excessive autophagy (MIM 310440)
(ref. 29)). Very recently, mutations in CCDC115 and TMEM199,
as predicted orthologs of yeast V-ATPase assembly factors
Vma22p and Vma12p, respectively, were identiﬁed in patients
with liver disease, elevated alkaline phosphatase and cholesterol,
mild abnormalities in copper metabolism and various degrees of
cognitive impairment39,40. No immune dysfunction was noticed.
The combination of clinical symptoms as observed in
Ac45-deﬁcient patients is currently poorly understood since
research on the functional roles of Ac45 has mainly been focused
on neuroendocrine cells and osteoclasts. Certain speciﬁc
symptoms could be related to other V-ATPase defects or known
roles of the V-ATPase complex. These include deafness as
reported in family 1, and also reported for ATP6V0A4 and
ATP6V1B1 defects. In addition, electron microscopy of a liver
biopsy of patient 3.1 suggested evidence for enhanced mitochon-
drial autophagy and muscle weakness with mildly elevated
creatine kinase was found in some patients. This could suggest
a partially overlapping disease mechanism with VMA21-deﬁcient
XMEA patients. Finally, in two of the patients, decreased
enamelization of the teeth was reported, which could correspond
with a recently reported role of V-ATPase-mediated acidiﬁcation
in enamelization41. Thus, likely at least some of the symptoms are
related to V-ATPase dysfunction, which is supported by our
studies on V-ATPase restricting growth conditions in yeast.
Immune and liver dysfunction have not yet been reported in
genetic defects of the V-ATPase, although liver disease was
recently described for defects in V-ATPase assembly factors
TMEM199 and CCDC115 (refs 39,40). The question is why these
systems are affected. Possible explanations could include the
tissue-speciﬁc processing of Ac45 or the existence of additional
functions of Ac45 beyond pH regulation via its effect on the
V-ATPase. Our studies in human hepatocytes show that Ac45, in
contrast to what was observed in neuroendocrine cells, mostly
localizes to the early secretory pathway. This is in agreement
with the presence of mostly intact-Ac45 carrying non-processed
high-mannose glycans. Further studies are needed to elucidate
the mechanisms driving differential Ac45 glycosylation and
processing in brain, liver and immune cells, since tissue-speciﬁc
forms of Ac45 could suggest a possible mechanism for the
tissue-restricted disease symptoms in Ac45-deﬁcient patients.
Thus far, the relationship of Ac45 with immune deﬁciency has
remained unnoticed. In view of the reported multiple functions of
Ac45 in, for example, pH regulation and membrane trafﬁcking
and fusion18, many possible links exist. Acidiﬁcation of
phagolysosomes in, for example, macrophages is important for
killing of internalized microorganisms, while antigen processing
is also dependent on acidic pH. Our growth assay in yeast under
conditions that are dependent on V-ATPase activity support the
notion that the patients’ phenotypes could be related to aberrant
acidiﬁcation due to dysfunction of the V-ATPase. Membrane
trafﬁcking and fusion events have not only been linked to
V-ATPase function42–44 but also to Ac45 (refs 18,43). These
events are reported to be required for B-cell differentiation45,
antigen processing46,47 and antibody production45. Thus,
pathogenic mutations in ATP6AP1 might affect B-cell function
at all these levels, resulting in decreased levels of
immunoglobulins and recurrent infections in our patients. The
observed hypoglycosylation on serum transferrin in our patients
might indicate hypoglycosylation on other proteins as well.
Several membrane-bound proteins such as CD19 and CD40 that
are involved in B-cell activation are glycosylated, and antigen
recognition and antibody production by B cells require
fucosylated IgG-BCR48. A glycosylation defect therefore may
affect B-cell activation and thus antibody production. To ﬁnd out
which processes, that is, glycosylation, vesicular trafﬁcking and
fusion, or pH regulation are mainly affecting antibody production
by a defective accessory subunit of the V-ATPase, further studies
are required.
Previous studies have described an important role for
Ac45 in intraorganellar pH regulation and membrane
trafﬁcking10,14–16,30. Identiﬁcation of processed Ac45 as the
functional ortholog of yeast V-ATPase assembly factor Voa1 only
when the KKNN ER retention signal is present, indicates the
importance of ER localization for its function in yeast, and
provides a valuable model to further dissect the different
functions and functional domains of Ac45. As the human
ortholog lacks this dilysine motif, other mechanisms might
account for retention of Ac45 to the ER of speciﬁc cell types
such as liver cells. Our observation in liver cells that the Ac45
protein is mostly present in its unprocessed form, which in
neuroendocrine cells appears to implicate ER localization12,15,18,
combined with its observed steady-state localization in the early
secretory pathway (ER, ERGIC) in hepatocytes, suggests that
differential proteolytic processing might represent such a
mechanism.
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In summary, the identiﬁcation of tissue-speciﬁc proteolytic
processing of Ac45, and the availability of Voa1 mutant yeast as
valuable model to further dissect the individual functions of Ac45
will facilitate future research to understand the functional roles
and isoforms of Ac45 in the immune system, liver, muscle and
brain and its relation to the V-ATPase in human. Screening
for abnormal protein glycosylation in plasma of patients with
hepatopathy and immune dysfunction with or without neuro-
logical symptoms provides a rapid way to identify additional
individuals with ATP6AP1 deﬁciency.
Methods
Patients and glycosylation studies. Blood and ﬁbroblasts of patients (clinical
information in Table 1) were obtained for diagnostics of inborn errors of
metabolism and used after informed consent from parents and/or treating
physicians. Isoelectric focusing of serum transferrin for analysis of protein
N-glycosylation defects and of serum apolipoprotein CIII for analysis of mucin
type O-glycosylation defects were carried out as described before49. Plasma
N-glycan proﬁling was performed by MALDI linear ion trap mass spectrometry
as described50 using 10 ml of plasma. Brieﬂy, serum was treated with PNGaseF,
free N-glycans were permethylated, extracted and dried, puriﬁed and spotted onto
a MALDI plate. Samples were dried and measured on a linear ion trap mass
spectrometer. High resolution mass spectrometry of intact serum transferrin was
performed as described51. Brieﬂy, transferrin was immunopuriﬁed from 10 ml
serum using anti-transferrin Sepharose beads. The elution with glycine-HCl pH 2.7
was neutralized by Tris-HCl pH 9.0 and was directly available for injection onto the
nanoLC-C8-chip of the QTOF. Transferrin was eluted from the chip in a 10min
gradient of H2O and Acetonitrile, 0.1% formic acid. Charge distribution raw data
were deconvoluted by Mass Hunter software to reconstructed mass spectra51.
Next-generation sequencing. Genomic DNA was extracted from patient
ﬁbroblast according to the manufacturer’s protocol using a Qiagen Mini kit
(Qiagen, Hilden, Germany), and was checked for DNA integrity on agarose gels.
Next-generation sequencing and analysis was performed as described28. In brief,
exome enrichment was performed using the SureSelect Human All Exon 50Mb Kit
(Agilent, Santa Clara, CA), covering B21,000 genes. The exome library was
sequenced on a SOLiD 5500xl sequencer (Life Technologies, Foster City, CA,
USA). Colour space reads were iteratively mapped to the hg19 reference genome
with the SOLiD LifeScope software version 2.1. Called variants and indels were
annotated using an in-house annotation pipeline52,53 and common variants were
ﬁltered out based on a frequency of 40.5% in dbSNP (137) and a frequency of
40.3% in our in-house database of 41,300 exomes. Quality criteria were applied
to ﬁlter out variants with o5 variant reads and o20% variation. Furthermore,
synonymous variants, deep intronic, intergenic and UTR variants were
excluded. Raw data of candidate variants were inspected using the Intergrative
Genomic Viewer software (IGV browser) version 2.3.14 (2013) (ref. 54)
(http://www.broadinstitute.org/igv/download). The putative consequences of
the mutations found in the Ac45 protein were predicted using Sift (2009)
(http://sift.jcvi.org/www/SIFT_aligned_seqs_submit.html), Mutation taster, (2014)
(http://www.mutationtaster.org/) and Polyphen-2 (2012) (http://genetics.bwh.
harvard.edu/pph2/) prediction programs.
Sanger sequencing. Genomic DNA was extracted from ﬁbroblast pellets
or white blood cells from 10 patients and available family members. Primers
(Supplementary Table 4) were designed to amplify the 10 exons of ATP6AP1
(GenBank accession number NM_001183.4), including at least 50 bp of the
ﬂanking intronic regions. Standard PCR reactions were based on 1 ml DNA and
0.2 ml Platinum Taq polymerase (Invitrogen) in a total volume of 25 ml. Standard
reaction conditions were 10min at 95 C, then 35 cycles of 30 s at 95 C, 30 s at
60 C and 1min at 72 C. The reaction was completed with a ﬁnal elongation of
7min at 72 C. For the sequencing of the resulting PCR product, the BigDye
Terminator Ready reaction cycle sequencing kit v.3.1 (Applied Biosystems) was
used. Analysis of the results was performed on an ABI3100 Avant (Applied
Biosystems).
ATP6AP1 gene expression proﬁling in human tissues by qPCR. Total RNA
from different human adult and fetal tissues was ordered from Stratagene Europe
(Amsterdam, The Netherlands). All fetal tissues are from 20- or 21-week-old
embryos after gestation. RNA was isolated using the NucleoSpin RNA II kit
(Macherey-Nagel, Du¨ren, Germany) according to the manufacturer’s protocols.
To remove residual traces of genomic DNA, the RNA was treated with DNase I
(Invitrogen, Leek, The Netherlands) while bound to the RNA binding column. The
integrity, concentration and purity of the RNA were assessed using agarose gel
electrophoresis and spectrometry. Of all tissues, 5 mg of total RNA was transcribed
into cDNA by using the iScript cDNA synthesis kit (Bio-Rad Laboratories,
Hercules, CA, USA) according to the manufacturer’s protocol. cDNA was puriﬁed
by using the NucleoSpin extract II kit (Macherey-Nagel) according to the
manufacturer’s protocol.
Quantitative PCR quantiﬁcations were performed in on the equivalent of
12.5 ng total RNA input using the Sensifast SYBR no ROX qPCR kit (Bioline)
and a Rotor-GeneTM 6000 real-time analyzer (Qiagen). qPCR program used
was (2min 95 C (5 s 95 C, 10 s 60 or 65 C and 15 s 72 C) 40 cycles). Two pairs
of intron-spanning ATP6 AP1 primers were used. Primers used are listed in
Supplementary Table 4. As reference transcripts, GUSB and PPIB were used.
qPCR data were analysed by using comparative quantitation and the relative
Q-values of the genes of interest calculated by equalizing the lowest Ct value to 1.
The normalization factor for the reference genes was determined using the
GeNORM program (medgen.ugent.be/genorm) and used to normalize the
Q-values. Individual experiments were performed in triplicate.
Western blot analysis of Ac45 in cells and tissues. B-cell isolation. Buffy coats
from two healthy donors, who gave written informed consent for scientiﬁc use
of the buffy coats, were purchased from Sanquin Blood Bank, Nijmegen, The
Netherlands. Peripheral blood mononuclear cells were isolated by density gradient
centrifugation (Lymphoprep; Nycomed Pharma, Roskilde, Denmark). CD19þ
B cells were positively selected using anti-CD19 magnetic microbeads (Miltenyi
Biotec, Utrecht, The Netherlands). The isolated human donor B cells were lysed in
cold lysis buffer (50mM Hepes pH 7.4, 140mM NaCl, 0.1% Triton-X100, 1%
Tween-20, 0.1% deoxycholate supplemented with complete protease inhibitor mix
(Roche Diagnostics)) to a ﬁnal concentration of around nine million B cells per
20 ml lysisbuffer.
Tissue lysates. Tissue samples were powdered using a vessel and liquid nitrogen
and subsequently lysed with cold lysis buffer to a ﬁnal concentration of 100mg
tissue sample per 500 ml lysis buffer. All samples were incubated on ice for 15min
and repeatedly shortly vortexed during the incubation. Then, the homogenates
were centrifuged at 14,000 RCF for 10min, after which the supernatants were
collected. Subsequent PNGase F treatment was done as follows: supernatant
containing 21 mg of protein was incubated for 4–6 h at 37 C with 2.5 ml of
500,000Uml 1 of PNGase F (New England Biolabs) in a ﬁnal volume of 34 ml
containing 50mM sodium phosphate buffer pH 7.5 (G7 buffer from PNGase F kit,
New England Biolabs) and complete protease inhibitor mix (Roche Diagnostics).
A second incubation was performed overnight at 37 C after adding an additional
1 ml of PNGase F, 0.22 ml of G7 buffer, and 1 ml of protease inhibitor. The next day,
the tubes were shortly centrifuged, SDS sample buffer was added, and the samples
were boiled for 5min at 99 C. Samples were separated on 10% SDS–PAGE (7 mg of
protein per lane) and the proteins were transferred to a 0.2-mm polyvinylidene
diﬂuoride membrane. After blocking in 5% milk in PBSþ 1% Tween-20, the
membrane was incubated overnight at 4 C with primary antibody rabbit
anti-mouse Ac45 polyclonal #49 antiserum (directed towards A271-T283 and
L443-I457 of mouse Ac45, kindly provided by Dr J. Creemers, Catholic University,
Leuven, Belgium) at a dilution of 1:5,000 in blocking buffer. Goat-anti rabbit-HRP
secondary antibody (Dako, P0448) at a dilution of 1:5,000 in 2.5% milk in PBS-1%
Tween-20 were used for ECL detection. To check for protein loading, the
membrane was incubated with mouse anti-GapdH monoclonal antibody
(Ab8245-100, Abcam) at a dilution of 1:2,000 in 3% BSA in PBS/0.1%
Tween-20 for 1 h at room temperature. Incubation with the secondary antibody
(Goat-anti-mouse-HRP, Dako P0447) was for 1 h at room temperature at a dilution
of 1:5,000 in 2.5% milk in PBS-1% Tween-20. Chemoluminescent signals was
detected using ECL (Pierce).
Biochemical studies in immortalized human hepatocytes. IHH55 were
cultured in gelatin-coated culture ﬂasks in Williams medium E supplemented with
10% FCS, 0.022Uml 1 insulin and 0.045mgml 1 dexametasone. Culturing was
done at 37 C under an atmosphere of 5% CO2. IHH cell cultures were tested
negative for mycoplasm. For Ac45 expression, IHH cells were transfected with a
hsAc45/pcDNA3 construct using Lipofectamine LTX (Invitrogen) according to
manufactures’ guidelines.
For immunoﬂuorescence assays, cells were cultured on gelatin-coated cover
slips for 3 days and ﬁxed for 1 h by 4% paraformaldehyde in PBS at room
temperature. After blocking of residual parafomaldehyde with 50mM NH4Cl in
PBS, cells were permeabilized using 0.1% Triton-X100 in PBS (PBS-T) and
incubated with anti-Ac45 antibody (1:1,000) and mouse-anti-EEA1 (BD
Biosciences, 1:200), mouse-anti-M6PR (Abcam, 1:200), mouse-anti-Sec31a (Santa
Cruz, 1:200), mouse-anti-GM130 (BD Transduction Laboratories, 1:400), mouse-
anti-PDI (Stressgen, 1:500), mouse-anti-Rab11 (BD Biosciences, 1:100), mouse-
anti-ERGIC53 (Santa Cruz, 1:100) and goat-anti-TGN38 (Santa Cruz, 1:100)
antibodies in 1% BSA in PBS-T (blocking buffer) for 12 h at 4 C. After washing
with PBS-T, cells were incubated for 45min at room temperature with secondary
antibodies Goat-anti-rabbit-Alexa488 and Goat-anti-mouse-Alexa568 or Donkey-
anti-rabbit-Alexa488 combined with Donkey-anti-goat-Alexa568 at a dilution of
1:200 in blocking buffer. Hereafter, cells were washed with PBS-T, PBS, MilliQ
water and dehydrated using methanol and subsequently mounted in Mowiol
containing 2.5 mM DAPI. Imaging was performed using an Olympus FV1000
confocal laser scanning microscope using a  63 oil objective. All images were
captured with an aspect ratio of 1,200 1,200 using the FluoView version 4.1
software at a scanning speed of 12.5 ms per pixel. Image analysis was performed
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using Fiji software. Relative ﬂuorescence intensities were calculated over a 10-mm
cross section by setting the highest measured value to 100.
Newly synthesized protein labelling experiments. Two days prior to labelling,
IHH cells were seeded into gelatin-coated 12-well plates at a density of 2 105 cells
per well. Cells were washed using PBS and starved in starvation medium
(DMEM without methione and cysteine, supplemented with 10% dialysed FCS,
0.022Uml 1 insulin and 0.045mgml 1 dexametasone) for 1 h. Then, cells
were incubated for a 30-min pulse period in starvation medium containing
0.1mCiml 1 EasyTag EXPRESS 35S protein labelling Mix (PerkinElmer). For
analysis of the N-glycosylation of Ac45, the 30-min pulse was carried out in the
presence of tunicamycin. Following the pulse period, cells were washed with PBS
and lysed in lysis buffer. For immunoprecipitation, lysates were incubated with
anti-Ac45 antibodies (1:500) in lysis buffer supplemented with 0.8% SDS for 12 h
at 4 C. Immune complexes were precipitated by Protein A-sepharose (GE
Healthcare Life Sciences) and resolved on 10% SDS–PAGE. EndoH (New
England Biolabs) and PNGaseF (New England Biolabs) treatment was performed
on immunoprecipitated Ac45 protein according to manufacturer’s guidelines.
Radiolabelled proteins were visualized by ﬂuorography.
Transmission electron microscopy. The tissue cylinder was immediately
immersed in cold 2.5% glutaraldehyde in 0.1M Cacodylate buffer (pH 7.4) for 2 h.,
post ﬁxed in 1% osmium tetroxide for 1 h., dehydrated through ethanol series and
embedded in epoxy resin. Semi-thin sections (1 mm) stained with 1% toluidine blue
were used for orientation, cell identiﬁcation and gross histopathological changes
(that is, lipid droplets). Ultrathin sections (60 nm) were cut with diamond knives
and either left unstained or stained with uranyl acetate and lead citrate. Sections
from three blocks were placed on 300-mesh copper grids and viewed and
photographed with JEOL JEM 100SX and 100CX electron microscopes, operated
at 80 kV.
Bio-informatics studies. For sequence-proﬁle-based homology searching, we used
HHpred56 with three PSI-Blast iterations to create the initial sequence proﬁles. The
initial proﬁles were based either on Ac45 after which that proﬁle was compared
with the proﬁles of S. cerevisiae and S. pombe, on Voa1 after which that proﬁle was
compared to the proﬁles of H. sapiens, or with Big1 after which that proﬁle was
compared with the proﬁles of H. sapiens. The expectation values (E-values)
obtained via homology detection using HHpred55 with the sequence proﬁle
based on Ac45 (arrows from Ac45 outwards) and for the reciprocal searches
with Voa1/Big1 (arrows towards Ac45) are indicated in Fig. 5a.
Yeast strain and plasmids. Standard molecular biology protocols for E. coli and
yeast manipulations were followed57. The voa1::H vma21QQ yeast strain used in
this study is isogenic with SF838-1Da (MATa ura3-52 leu2-3,112 his4-519 ade6
pep4-3 gal2) (ref. 58) and additionally has voa1::Hygr vma21QQ::HA (MRY5)
(ref. 24). Plasmids used are listed in Supplementary Table 5. All pMR plasmids
have in common the pRS316 vector59, 821 bp of VOA1 50 UTR sequence, coding
sequence for Voa1 signal peptide (M1–A24), and the ﬁrst Voa1 amino acid after
signal cleavage (D25) followed by a single HA tag or HA-GFP. Sequence coding for
C-terminal KKNN of Voa1 was added to Ac45 where indicated. All pMR plasmids
have 245 bp of VOA1 30 UTR ﬂanking sequence.
A pMR072 (ref. 24) derived precursor plasmid, pMR124, was prepared where
Voa1 amino acids I218–I261 are replaced with human Ac45 F421–V470 by using
yeast codon optimized oligonucleotides and PCR. pMR1210 was prepared from
pMR124 by replacing Voa1 S26–S217 with human Ac45 Q43–S420, PCR ampliﬁed
from pOTB7/ATP6AP1 (MGC cDNA clone, IMAGE:3506925, Thermo Scientiﬁc),
using the FastCloning technique60. Thus pMR1210 encodes full-length
Ac45-KKNN. KKNN was deleted from the C-terminal end of Ac45 in pMR1210,
giving pMR1211. The N-terminal half of Ac45 (Q43-V250) was deleted in
pMR1210 and pMR1211, resulting in pMR1213 and pMR1214, respectively.
Primers designed to produce mutation Y313C, E346K or M428I and pMR1213
template were used to make pMR1213Y313C, pMR1213E346K or pMR1213M428I.
pMR092 was made by inserting mGFP5(S65T)61 into pMR072 between the HA tag
and Voa1 S26 using PCR techniques. Inverse PCR with primers encoding K262Q
and K263Q mutations and pMR092 template produced pMR1312. pMR1303 and
pMR1304 were made from pMR1213 and pMR1214, respectively, by inserting
GFP immediately after the HA tag. E346K and M428I mutations were made in
pMR1303, resulting in pMR1303E346K and pMR1303M428I, respectively. Coding
sequence region in all plasmid constructs was veriﬁed by DNA sequencing.
Yeast growth assay. Liquid cultures of yeast strains were grown overnight at
30 C in synthetic minimal medium plus dextrose (SD) supplemented to select for
plasmid (-Ura), diluted to 0.4 OD600 per ml in rich medium (YEPD) buffered to
pH 5 with 50mM succinate/phosphate, and grown until densities reached 1
OD per ml. Cells were pelleted and suspended to 0.8 OD per ml in H2O. This
suspension and serial 1:8 dilutions were spotted onto YEPD pH 5 and restrictive
medium (100mM CaCl2 in pH-unadjusted YEPD, or 60mM CaCl2 in YEPD
buffered to pH 7.5 with 50mM HEPES). Growth was recorded after 46 h
incubation at 30 C.
Western blot analysis of yeast proteins. Yeast membrane proteins were
prepared from glass-bead lysates by centrifugation at 13,000g as described24.
The pelleted membrane fraction was solubilized in sample buffer (8M urea,
5% SDS, 40mM Tris-HCl pH 6.8, 5% b-mercaptoethanol, 0.01% bromophenol
blue) to 100 OD600 equivalents per ml, and 0.5 OD equivalents separated by
SDS–PAGE. Proteins were transferred to nitrocellulose membrane and analysed
by western blot using a 1:300 dilution of monoclonal anti-HA primary antibody
(BioLegend) and a 1:15,000 dilution of goat anti-mouse secondary antibody
labelled with IRDye 800CW (LI-COR). Blocking of non-speciﬁc binding and
incubation with antibody was done in 5% non-fat dry milk, 0.1% TWEEN 20,
0.5M NaCl, 20mM Tris-HCl pH 7.5. Wash steps after antibody incubation were in
the same buffer but without milk. Before imaging (Odyssey Fc Imager, LI-COR),
a ﬁnal wash was done in 10mM Tris-HCl pH 7.5, 150mM NaCl.
Live cell imaging of yeast cells. Yeast cells expressing GFP-tagged proteins were
grown overnight in SD-Ura, diluted to 0.2 OD600 per ml in SD-Ura containing
2.5 mgml 1 DAPI (Sigma) and grown until 0.4 OD600 per ml. Cells were collected
by centrifugation, and 1.5 ml of cell pellet was added to an equal volume of molten
1% agarose on a glass slide for live cell imaging. Images were acquired with
an Axioplan 2 ﬂuorescence microscope (Carl Zeiss) using a  100 objective.
Axiovision (Carl Zeiss) and ImageJ (http://imagej.nih.gov/ij) software were used
for image evaluation, and Photoshop CS4 for image manipulation.
Data availability. The authors declare that all data supporting the ﬁndings of this
study are available within the article and its Supplementary Information ﬁles.
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